| abstract |
A purpose of the present invention is to provide an immunopotentiator that reduces Treg cells (in particular, effector Treg cells) and thus potentiates tumor immunity or infection immunity.nImatinib and/or a salt thereof have a function of reducing Treg cells (in particular, effector Treg cells) and thus potentiating tumor immunity or infection immunity and, therefore, are usable as an active ingredient of an immunopotentiator. |